Direkt zum Inhalt
Merck

A sustained intravitreal drug delivery system with remote real time monitoring capability.

Acta biomaterialia (2015-06-19)
Huiyuan Hou, Alejandra Nieto, Akram Belghith, Kaihui Nan, Yangyang Li, William R Freeman, Michael J Sailor, Lingyun Cheng
ZUSAMMENFASSUNG

Many chorioretinal diseases are chronic and need sustained drug delivery systems to keep therapeutic drug level at the disease site. Many intravitreal drug delivery systems under developing do not have mechanism incorporated for a non-invasive monitoring of drug release. The current study prepared rugate porous silicon (pSi) particles by electrochemical etching with the current frequency (K value) of 2.17 and 2.45. Two model drugs (rapamycin and dexamethasone) and two drug-loading strategies were tested for the feasibility to monitor drug release from the pSi particles through a color fundus camera. The pSi particles (k=2.45) with infiltration loading of rapamycin demonstrated progressively more violet color reflection which was negatively associated with the rapamycin released into the vitreous (r=-0.4, p<0.001, pairwise). In contrast, pSi with K value of 2.17 demonstrated progressive color change toward green and a weak association between rapamycin released into vitreous and green color abundance was identified (r=-0.23, p=0.002, pairwise). Dexamethasone was covalently loaded on to the fully oxidized pSi particles that appeared in vitreous as yellow color and fading over time. The yellow color decrease over time was strongly associated with the dexamethasone detected from the vitreous samples (r=0.7, p<0.0001, pairwise). These results suggest that engineered porous silicon particles may be used as a self-reporting drug delivery system for a non-invasive real time remote monitoring. The current study, for the first time, demonstrated proof of concept that engineered porous silicon photonic crystal may deliver therapeutics in a controlled fashion while at the same time might offer a noninvasive remote monitoring of its payload release in a living eye. Porous silicon photonic crystal changes color which is in association with its payload release into vitreous. With further optimization, the color change may be harnessed to inform eye care professionals of real time drug concentration in the eye and allow them to make informed decision to re-dose the patients.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
N,N-Dimethylformamid, anhydrous, 99.8%
Sigma-Aldrich
Dichlormethan, anhydrous, ≥99.8%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
Acetonitril, anhydrous, 99.8%
Sigma-Aldrich
Ethyl alcohol, Pure, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
Toluol, anhydrous, 99.8%
Sigma-Aldrich
Salzsäure -Lösung, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethyl alcohol, Pure, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
N,N′-Dicyclohexylcarbodiimid, 99%
Sigma-Aldrich
(3-Aminopropyl)trimethoxysilan, 97%
Sigma-Aldrich
Salzsäure, 36.5-38.0%, BioReagent, Molecular Biology
Sigma-Aldrich
N,N-Dimethylformamid, Molecular Biology, ≥99%
Supelco
Salzsäure -Lösung, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
Bernsteinsäureanhydrid, ≥99% (GC)
Sigma-Aldrich
Salzsäure -Lösung, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
Rapamycin, Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus
Sigma-Aldrich
Acetonitril, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
Chlorwasserstoff, ReagentPlus®, ≥99%
Sigma-Aldrich
Chlorwasserstoff -Lösung, 3 M in cyclopentyl methyl ether (CPME)
Sigma-Aldrich
Salzsäure -Lösung, 32 wt. % in H2O, FCC
Sigma-Aldrich
N,N′-Dicyclohexylcarbodiimid -Lösung, 1.0 M in methylene chloride
Sigma-Aldrich
Aceton, ≥99%, FCC, FG
Sigma-Aldrich
Dichlormethan, suitable for HPLC, ≥99.9%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
Aceton, natural, ≥97%
Sigma-Aldrich
Aceton, suitable for HPLC, ≥99.9%